naphthalene-2-carboxylic acid (4-iodo-1-methyl-1H-indazol-3-yl)amide | 883001-02-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: naphthalene-2-carboxylic acid (4-iodo-1-methyl-1H-indazol-3-yl)amide
• 英文别名: Naphthalene-2-carboxylic acid (4-iodo-1-methyl-1H-indazol-3-yl)-amide；N-(4-iodo-1-methylindazol-3-yl)naphthalene-2-carboxamide
• CAS: 883001-02-3
• 化学式: C₁₉H₁₄IN₃O
• 分子量: 427.244
• InChiKey: QYXFXCSUWPLKBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  naphthalene-2-carboxylic acid (4-iodo-1-methyl-1H-indazol-3-yl)amide 、 丙烯酸甲酯（MA） 在 palladium diacetate 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 反应 12.5h， 生成 (E)-3-{1-methyl-3-[(naphthalene-2-carbonyl)amino]-1H-indazol-4-yl}acrylic acid methyl ester
  参考文献：
  名称：

  Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding

  摘要：

  The EP(3) receptor on the platelet mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP(3) receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged oil a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.

  DOI：

  10.1021/jm9005912
• 作为产物：
  描述：

  4-iodo-1-methyl-1H-indazol-3-amine 、 2-萘甲酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以65%的产率得到naphthalene-2-carboxylic acid (4-iodo-1-methyl-1H-indazol-3-yl)amide
  参考文献：
  名称：

  Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding

  摘要：

  The EP(3) receptor on the platelet mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP(3) receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged oil a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.

  DOI：

  10.1021/jm9005912

文献信息

• WO2006/44415
  申请人：——

  公开号：——

  公开（公告）日：——
• SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE
  申请人：DECODE GENETICS, EHF

  公开号：EP1812388B1

  公开（公告）日：2011-02-23